# Adjuvanted Seasonal Recombinant Quadrivalent Virus-Like Particles (QVLP) Influenza Vaccine in Adults 65 Years of Age and Older

> **NCT04622592** · PHASE1,PHASE2 · COMPLETED · sponsor: **Medicago** · enrollment: 209 (actual)

## Conditions studied

- Influenza

## Interventions

- **BIOLOGICAL:** Instramuscular vaccine

## Key facts

- **NCT ID:** NCT04622592
- **Lead sponsor:** Medicago
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-11-02
- **Primary completion:** 2022-04-26
- **Final completion:** 2022-04-26
- **Target enrollment:** 209 (ACTUAL)
- **Last updated:** 2023-07-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04622592

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04622592, "Adjuvanted Seasonal Recombinant Quadrivalent Virus-Like Particles (QVLP) Influenza Vaccine in Adults 65 Years of Age and Older". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT04622592. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*